Target intelligence / Profile preview

Intracellular protein with metal-chelating site

Molecular classification
Enzyme, Transporter, Regulatory protein, Metal storage protein, Other
01

Overview

Intracellular proteins with metal-chelating sites comprise a heterogeneous group of proteins that possess amino acid residues (e.g., cysteine, histidine, glutamate, aspartate) forming binding pockets or sites able to tightly coordinate metal ions such as iron, copper, zinc, and manganese. This capability underlies crucial physiological roles in metal transport, storage, detoxification, and enzymatic reactions. Representative examples include metallothioneins (primarily metal storage and detoxification), enzymes such as monoamine oxidase and superoxide dismutase, and transporters like cation diffusion facilitators. Dysregulation of these proteins or their metal-binding properties contributes to the pathogenesis of diverse diseases, including neurodegenerative disorders, cancer, and systemic metal overload. While these proteins are not typically drug targets themselves, their metal-binding properties are exploited therapeutically by chelating agents designed to modulate metal ion bioavailability and mitigate metal-induced cellular toxicity.

Other names
Metal-binding intracellular proteinsIntracellular metal-chelating proteinsCellular metalloproteins
02

Mechanism of action

Chelation of metal ions, preventing excess accumulation and toxicity Enzyme inhibition (e.g., inhibiting MAO by chelating iron) Regulating oxidative stress via metal binding Modulation of cell signaling pathways involving metal ions

03

Biological functions

Metal ion homeostasisDetoxification and oxidative stress responseSignal transductionEnzymatic catalysisCellular transport (of metals)
04

Disease associations

Neurodegenerative diseaseCancerInflammationOther metabolic diseases
05

Safety considerations

Chelation therapy may cause essential metal depletion and off-target effectsDisruption of normal metalloprotein function leading to metabolic disturbancesRisk of oxidative stress if metal homeostasis is impaired
06

Interacting drugs

Metal chelators (deferoxamine, deferasirox, penicillamine)

2 more in the full profile.

07

Biomarkers

Metallothionein expression levels (for heavy metal exposure)Transferrin saturation/levels (for iron metabolism)Altered metal-protein ratios in tissues (e.g., Cu/Zn SOD in ALS)

Beyond the preview

Go deeper on Intracellular protein with metal-chelating site.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intracellular protein with metal-chelating site.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call